US EditionPublished • loading... • Updated
NeoGenomics, Inc. (NEO) Stock Analysis: Assessing A 16.59% Potential Upside
Summary by DirectorsTalk Interviews
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
NeoGenomics, Inc. (NEO) Stock Analysis: Assessing A 16.59% Potential Upside
NeoGenomics, Inc. (NASDAQ: NEO) is garnering attention in the investment community with a promising 16.59% potential upside, according to recent analyst ratings. With its market cap standing at $1.62 billion, NeoGenomics operates within the healthcare sector, specifically in the diagnostics and research industry. This company is strategically positioned in the United States, a hub for cutting-edge medical advancements, and is making significant …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
